2025 · 4th Quarter (Oct 1 - Dec 31)

NOVARTIS

Filed by BROWNSTEIN HYATT FARBER SCHRECK, LLP.

Open official filing

Source-reported fields

Filing overview

Type: 4th Quarter - Report
Posted: Jan 20, 2026
Income: $70,000.00
Expenses: Not reported
Registrant: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Client: NOVARTIS
Filing UUID: 8ecd9c0d-fffc-4fd1-bb67-076f3e397e40
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy

Literal federal measure citations: HR 1672

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.